AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that it has dosed the first patient ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. CD19/CD20 Bi-Specific CAR-T ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...
Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis PURPOSE: To ...
Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of ...
Non-Hodgkin's lymphoma classifies common hematological neoplasms accounting for an estimated 19 500 US deaths in 2009, 1 with approximately 80–90% of cases involving B lymphocytes. Current therapeutic ...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 19 (COVID-19) pandemic. This pandemic has resulted in drastic healthcare and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results